Anti-HER2 CAR T cells were activated by MDA-MB-453 tumor cells or TransAct, which provides primary and co-stimulatory signals for T cell activation, and cytokine secretion and cytotoxicity were assessed under compound treatment. This evidence concerns the gene ERBB2 and neoplasm.